by Lindsay Shapiro, PhD | October 19, 2022
The National Institutes of Health (NIH) is supporting a university’s research into the risk factors and underlying mechanisms involved in the development of neutralizing antibodies, or inhibitors, against replacement therapies in people with hemophilia A.
The $6.6 million, three-year grant from the NIH’s National Heart, Lung, and Blood Institute comes with the possibility of additional funding for a proposed four-year second phase of this study.
Continue reading the article here.
